Clinical Trial Update: A Study of Trastuzumab Deruxtecan in People With Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating trastuzumab deruxtecan for non-small cell lung cancer is currently recruiting, including stage II, IIIA, and IIIB disease.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Trastuzumab deruxtecan (trastuzumab deruxtecan)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Non-Small Cell Lung Cancer, Non-small Cell Lung Cancer Stage II | Phase 2 | Status: RECRUITING